Table S1: Points of departure derived for monocrotalinea. Dose(mg/kg bw/day) T25 Species Gender Tumour Type Malignant T10 (mg/kg bw/day) (mg/kg bw/day) 0 2.5 Pulmonary adenocarcinoma Yes 3.8 1.5 0/45b 10/60 Pulmonary adenocarcinoma Yes 38 15 0/45 1/60 with metastases Hepatocellular carcinoma Yes 7.5 3.0 0/45 5/60 3/60 Rat Male Acute myelogenous leukemia Yes 13 5.2 0/45 Rhabdomyosarcoma Yes 9.4 3.8 0/45 4/60 Renal adenoma No 38 15 0/45 1/60 Peliosis hepatis No 4.7 1.9 0/45 8/60 Bile duct hyperplasia No 13 5.2 0/45 3/60 Adrenal adenoma No 6.7 2.7 2/45 8/60 a The data from Shumaker et al.(1976) b Italic number represents cancer incidence/total number of test animals
Table S1: Points of departure derived for monocrotalinea. Species Gender Tumour Type Malignant Dose(mg/kg bw/day) T25 (mg/kg bw/day) T10 (mg/kg bw/day) 0 2.5 Rat Male Pulmonary adenocarcinoma Yes 0/45b 10/60 3.8 1.5 Pulmonary adenocarcinoma with metastases Yes 0/45 1/60 38 15 Hepatocellular carcinoma Yes 0/45 5/60 7.5 3.0 Acute myelogenous leukemia Yes 0/45 3/60 13 5.2 Rhabdomyosarcoma Yes 0/45 4/60 9.4 3.8 Renal adenoma No 0/45 1/60 38 15 Peliosis hepatis No 0/45 8/60 4.7 1.9 Bile duct hyperplasia No 0/45 3/60 13 5.2 Adrenal adenoma No 2/45 8/60 6.7 2.7 a The data from Shumaker et al.(1976) b Italic number represents cancer incidence/total number of test animals
1-s2.0-S0273230017300776-mmc1.docx